CredibleMeds have reviewed the QT risk for the COVID-19 drug, remdesivir, and placed it in the Possible Risk category for torsade de pointes. Therefore, we have updated our interactions with the QT-prolonging HCC drugs lenvatinib and sorafenib from green to yellow.
We have also renamed the comedication Valproate (anticonvulsants class, known as Divalproex in the US) to help people find it. You will now find it listed as valproic acid, sodium valproate, and valproate semisodium.
